2BBBullish & Bearish
Repligen Corporation (RGEN) trades on NASDAQ. It operates in the Health Care sector, Medical Instruments & Supplies industry. Its current 2BB score is 62 out of 100.
Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN.
Repligen Corporation’s current 2BB score is 62 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 73 | High |
| Momentum | 50 | Stable |
| Financial strength | 73 | Strong |
| Quality | 98 | Very Strong |
| Risk | 17 | Very Low |
| CEO | Tony J. Hunt |
| Headquarters | Waltham, Massachusetts, United States |
| Founded | 1981 |
| Employees | 2K |
| P/E ratio | 242.90 |
| 52-week range | $100.99 – $198.86 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-22 | — | 0.5923 | — | $226.47M |
| 2026-11-03 | — | 0.4717 | — | $210.83M |
| 2026-07-28 | — | 0.4564 | — | $205.33M |
| 2026-05-05 | 0.48 | 0.3938 | $194.25M | $196.12M |